|
End-of-day quote
Korea S.E.
2026-10-20
|
5-day change | 1st Jan Change | ||
| 2,600.00 KRW | -0.95% |
|
-5.11% | -44.50% |
| 09-20 | Genexine, Inc.(KOSDAQ:A095700) dropped from S&P Global BMI Index | CI |
| 09-15 | Genexine Presents Preclinical Data For GX-BP1 SOX2 BioPROTAC At 2026 World Conference On Lung Cancer | CI |
Company Valuation: Genexine, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Market Cap 1 | 1,485,081 | 3,069,933 | 1,459,198 | 470,211 | 410,353 |
| Change | - | 106.72% | -52.47% | -67.78% | -12.73% |
| Enterprise Value (EV) 1 | 1,441,942 | 3,090,374 | 1,483,621 | 532,352 | 413,298 |
| Change | - | 114.32% | -51.99% | -64.12% | -22.36% |
| P/E | -80.7x | 142x | -30.2x | -8.34x | -5.99x |
| PBR | 5x | 5.73x | 2.84x | 1.72x | 1.38x |
| PEG | - | -1x | 0x | -0.5x | 1.44x |
| Capitalization / Revenue | 131x | 166x | 39.6x | 29.1x | 92.7x |
| EV / Revenue | 128x | 167x | 40.3x | 33x | 93.4x |
| EV / EBITDA | -34.3x | -85.3x | -93.9x | -18.5x | -11.2x |
| EV / EBIT | -32.4x | -78.9x | -77.7x | -15.8x | -9.86x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -595.4 | 671.5 | -1,483 | -1,724 | -1,652 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | 11,303 | 18,543 | 36,828 | 16,139 | 4,427 |
| EBITDA 1 | -42,070 | -36,231 | -15,801 | -28,808 | -36,897 |
| EBIT 1 | -44,573 | -39,151 | -19,099 | -33,680 | -41,928 |
| Net income 1 | -16,509 | 27,570 | -48,042 | -55,974 | -66,874 |
| Net Debt 1 | -43,139 | 20,441 | 24,423 | 62,141 | 2,945 |
| Reference price 2 | 48,076.92 | 95,615.38 | 44,846.15 | 14,384.62 | 9,900.00 |
| Nbr of stocks (in thousands) | 30,890 | 32,107 | 32,538 | 32,688 | 41,450 |
| Announcement Date | 3/12/21 | 3/12/21 | 3/17/22 | 3/20/23 | 3/13/24 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 89.65M | |
| 19.06x | 6.78x | 13.59x | 1.56% | 65.83B | |
| 35.71x | 6.35x | 18.96x | 0.91% | 51.87B | |
| 27.56x | 7.53x | 23.84x | 0.05% | 51.2B | |
| 33.88x | 3.31x | 14.28x | -.--% | 43.76B | |
| 48.73x | 5.61x | 30.83x | -.--% | 42.09B | |
| -18.92x | 193.08x | -20x | -.--% | 39.04B | |
| 29.6x | 8.38x | 21.69x | 0.36% | 34B | |
| 29.17x | 6.17x | 16.01x | -.--% | 25.2B | |
| 31.2x | 5.77x | 19.4x | -.--% | 22.8B | |
| Average | 26.22x | 27.00x | 15.40x | 0.32% | 37.59B | |
| Weighted average by Cap. | 25.99x | 25.69x | 15.50x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A095700 Stock
- Valuation Genexine, Inc.
Select your edition
All financial news and data tailored to specific country editions
